Patents Assigned to MEDIGENE IMMUNOTHERAPIES GMBH
-
Publication number: 20240083967Abstract: The present invention relates to the field of biotechnology. Specifically, the invention provides antigen-specific T-cell receptors (TCRs). Further, the invention encompasses polynucleotides encoding the same and vectors comprising said polynucleotides. Host cells comprising the molecules of the invention are also provided. Moreover, the invention provides means and methods for diagnostics and therapy, in particular of cancer.Type: ApplicationFiled: August 21, 2023Publication date: March 14, 2024Applicant: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Christian ELLINGER, Carina WEHNER, Manon WEIS, Susanne WILDE, Dolores SCHENDEL
-
Patent number: 11732020Abstract: The present invention relates to the field of biotechnology. Specifically, the invention provides antigen-specific T-cell receptors (TCRs). Further, the invention encompasses polynucleotides encoding the same and vectors comprising said polynucleotides. Host cells comprising the molecules of the invention are also provided. Moreover, the invention provides means and methods for diagnostics and therapy, in particular of cancer.Type: GrantFiled: June 16, 2017Date of Patent: August 22, 2023Assignee: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Christian Ellinger, Carina Wehner, Manon Weis, Susanne Wilde, Dolores Schendel
-
Publication number: 20230044580Abstract: The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: May 7, 2020Publication date: February 9, 2023Applicants: 2SEVENTY BIO, INC., MEDIGENE IMMUNOTHERAPIES GMBHInventors: JASDEEP MANN, CHRISTIAN ELLINGER, DANIEL SOMMERMEYER, BENJAMIN BOYERINAS
-
Patent number: 11292838Abstract: The invention relates to a method for generating an antibody binding to a cell surface protein of interest, the method comprising the following steps: (a) providing a non-human cell which does not express the endogenous form of the cell surface protein of interest but expresses an exogenous form of the cell surface protein of interest comprising at least one human segment; (b) immunization of a non-human animal with the cell line provided in step (a); (c) generation of hybridomas from the immunized non-human animal of step (b); (d) screening for an antibody that binds to the cell surface protein of interest by contacting the antibodies secreted by the hybridomas of step (c) with human cells which do not express the endogenous form of the cell surface protein of interest but express an exogenous form of the cell surface protein of interest comprising at least one human segment.Type: GrantFiled: June 1, 2016Date of Patent: April 5, 2022Assignee: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Dolores Schendel, Slavoljub Milosevic, Tanja Herrmann, Michaela Kügler
-
Patent number: 11267864Abstract: The present invention relates to an isolated T cell receptor (TCR) specific for NY-ESO-1/LAGE-1 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.Type: GrantFiled: January 28, 2019Date of Patent: March 8, 2022Assignee: Medigene Immunotherapies GmbHInventors: Carina Wehner, Manon Weis
-
Patent number: 11155589Abstract: The present invention contemplates methods for the generation of human antigen-specific T lymphocytes. The methods employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC class presentation of RNA coded proteins. Accordingly, the present invention concerns expression vectors comprising MHC class-II targeting signal and at least one antigen or fragment thereof and its use for the in vitro generation of antigen-specific T lymphocytes. T cell clones and T cell receptors (TCRs) specific for tumor antigens or viral antigens are also described.Type: GrantFiled: December 22, 2016Date of Patent: October 26, 2021Assignees: Medigene Immunotherapies GmbH, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Slavoljub Milosevic, Christian Ellinger, Carina Wehner, Dolores Schendel
-
Publication number: 20210038647Abstract: The present invention relates to (nucleic acids encoding) inducible T cell receptors (iTCRs), compositions and kits, vectors and host cells comprising such (nucleic acids encoding) inducible T cell receptors, uses thereof in preparing inducible T cell receptors and host cells comprising such T cell receptors, methods for preparing such inducible T cell receptors and for dimerizing T cell receptors, as well as medical uses of such compounds and pharmaceutical compositions comprising them, particularly for treating cancer. The present invention relates to combinations comprising one or more nucleic acid molecules, said one or more nucleic acid molecules comprising a nucleic acid sequence A encoding for a TCR alpha chain linked to a dimerization domain, and a nucleic acid sequence B encoding for a TCR beta chain linked to a dimerization domain, as well as proteins encoded by such nucleic acid molecules and corresponding uses and methods.Type: ApplicationFiled: March 13, 2019Publication date: February 11, 2021Applicant: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Slavoljub MILOSEVIC, Adriana NEVES, Kristina SCHOEDEL, Alexander SCHMIDT
-
Patent number: 10882891Abstract: The present invention contemplates dendritic cell compositions. The dentritic cell compositions employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC II presentation of the antigen or fragment thereof. In particular, the invention refers to a dendritic cell vaccine comprising dendritic cells expressing a MHC class-II targeting signal fused to an antigen or fragment thereof. Dendritic cell vaccines for the stimulation of an immune response against melanoma-associated antigen are also described.Type: GrantFiled: December 22, 2016Date of Patent: January 5, 2021Assignees: MEDIGENE IMMUNOTHERAPIES GMBH, HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Slavoljub Milosevic, Christian Ellinger, Carina Wehner, Dolores Schendel
-
Patent number: 10858760Abstract: The invention relates to a library for the expression of all functional TCR types comprising 45 TCR constructs each encoding one of the 45 different TCR ? chains and 47 TCR constructs each encoding one of the 47 different TCR ? chains, wherein each of the 45 TCR constructs encoding one of 45 different TCR ? chain comprises the following building blocks one of the variable AV segments AVseg1 to AVseg45, and a constant AC segment, and wherein each of the 47 TCR constructs encoding one of 47 different TCR ? chains comprises one of the variable BV segments BVseg1 to BVseg47, and a constant BC segment.Type: GrantFiled: June 1, 2016Date of Patent: December 8, 2020Assignee: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Dolores Schendel, Slavoljub Milosevic, Christian Ellinger, Carina Wehner
-
Publication number: 20200148738Abstract: The present invention relates to an isolated T cell receptor (TCR) specific for NY-ESO-1/LAGE-1 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.Type: ApplicationFiled: January 28, 2019Publication date: May 14, 2020Applicant: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Carina WEHNER, Manon WEIS
-
Publication number: 20190169261Abstract: The present invention relates to the field of biotechnology. Specifically, the invention provides antigen-specific T-cell receptors (TCRs). Further, the invention encompasses polynucleotides encoding the same and vectors comprising said polynucleotides. Host cells comprising the molecules of the invention are also provided. Moreover, the invention provides means and methods for diagnostics and therapy, in particular of cancer.Type: ApplicationFiled: June 16, 2017Publication date: June 6, 2019Applicant: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Christian ELLINGER, Carina WEHNER, Manon WEIS, Susanne WILDE, Dolores SCHENDEL
-
Publication number: 20190002515Abstract: The present invention contemplates methods for the generation of human antigen-specific T lymphocytes. The methods employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC class presentation of RNA coded proteins. Accordingly, the present invention concerns expression vectors comprising MHC class-II targeting signal and at least one antigen or fragment thereof and its use for the in vitro generation of antigen-specific T lymphocytes. T cell clones and T cell receptors (TCRs) specific for tumor antigens or viral antigens are also described.Type: ApplicationFiled: December 22, 2016Publication date: January 3, 2019Applicants: MEDIGENE IMMUNOTHERAPIES GMBH, HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Slavoljub MILOSEVIC, Christian ELLINGER, Carina WEHNER, Dolores SCHENDEL
-
Publication number: 20190000949Abstract: The present invention contemplates dendritic cell compositions. The dentritic cell compositions employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC II presentation of the antigen or fragment thereof. In particular, the invention refers to a dendritic cell vaccine comprising dendritic cells expressing a MHC class-II targeting signal fused to an antigen or fragment thereof. Dendritic cell vaccines for the stimulation of an immune response against melanoma-associated antigen are also described.Type: ApplicationFiled: December 22, 2016Publication date: January 3, 2019Applicants: MEDIGENE IMMUNOTHERAPIES GMBH, HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Slavoljub MILOSEVIC, Christian ELLINGER, Carina WEHNER, Dolores SCHENDEL